Last reviewed · How we verify
continuous intravenous sufentanil 0.02μg•kg-1•h-1 infusion
continuous intravenous sufentanil 0.02μg•kg-1•h-1 infusion is a Small molecule drug developed by Jin Ni. It is currently FDA-approved.
At a glance
| Generic name | continuous intravenous sufentanil 0.02μg•kg-1•h-1 infusion |
|---|---|
| Sponsor | Jin Ni |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- continuous intravenous sufentanil 0.02μg•kg-1•h-1 infusion CI brief — competitive landscape report
- continuous intravenous sufentanil 0.02μg•kg-1•h-1 infusion updates RSS · CI watch RSS
- Jin Ni portfolio CI
Frequently asked questions about continuous intravenous sufentanil 0.02μg•kg-1•h-1 infusion
What is continuous intravenous sufentanil 0.02μg•kg-1•h-1 infusion?
continuous intravenous sufentanil 0.02μg•kg-1•h-1 infusion is a Small molecule drug developed by Jin Ni.
Who makes continuous intravenous sufentanil 0.02μg•kg-1•h-1 infusion?
continuous intravenous sufentanil 0.02μg•kg-1•h-1 infusion is developed and marketed by Jin Ni (see full Jin Ni pipeline at /company/jin-ni).
What development phase is continuous intravenous sufentanil 0.02μg•kg-1•h-1 infusion in?
continuous intravenous sufentanil 0.02μg•kg-1•h-1 infusion is FDA-approved (marketed).